Genetic Markers Associated with Early Cancer-Specific Mortality
By LabMedica International staff writers Posted on 08 May 2013 |
An analysis has found that the loss or amplification of particular DNA regions contributes to the development of prostate cancer.
Novel effectors and markers of localized but potentially life-threatening prostate cancer (PCa) have been identified by evaluating chromosomal copy number alterations (CNAs) in tumors from patients who underwent prostatectomy.
A team of scientists at Wake Forest School of Medicine (Winston-Salem, NC, USA) used a method that can detect these genetic changes in cells from prostate tumors from 125 patients who underwent radical prostatectomy between 1988 and 2004. A second cohort included 103 prostatectomy patients who were treated between 2002 and 2008 with a median follow-up of approximately five years most of whom had a less aggressive form of PCa.
CNAs in tumor DNA samples from 125 patients in the discovery cohort who underwent prostatectomy were assayed with high-resolution Affymetrix 6.0 single-nucleotide polymorphism microarrays (Santa Clara, CA, USA) and then were analyzed using the Genomic Identification of Significant Targets in Cancer (GISTIC) algorithm.
The investigators found that changes in 20 gene regions were likely contribute to prostate cancer development and changes in seven of the 20 regions were linked with early death from prostate cancer. Patients whose cancer cells had a loss of the gene that encodes for phosphatase and tensin homolog protein (PTEN) and an amplification of the gene that encodes for myelocytomatosis viral oncogene homolog (MYC) were more than 50 times as likely to die from prostate cancer than other patients who had similarly staged tumors and prostate-specific antigen levels at the time of diagnosis. Analyses of 333 tumors from additional patients confirmed the link between PTEN and MYC and prostate cancer lethality.
The genetic changes involved in the development and progression of prostate cancer may help guide doctors as they weigh different treatment options for patients with the disease. Jianfeng Xu, MD, DrPh, the senior author said, “Prostate cancer patients who have DNA copy number alterations at PTEN and MYC may not be appropriate candidates for active surveillance and should be treated intensively.” The study was published on April 22, 2013, in the journal Cancer.
Related Links:
Wake Forest School of Medicine
Affymetrix
Novel effectors and markers of localized but potentially life-threatening prostate cancer (PCa) have been identified by evaluating chromosomal copy number alterations (CNAs) in tumors from patients who underwent prostatectomy.
A team of scientists at Wake Forest School of Medicine (Winston-Salem, NC, USA) used a method that can detect these genetic changes in cells from prostate tumors from 125 patients who underwent radical prostatectomy between 1988 and 2004. A second cohort included 103 prostatectomy patients who were treated between 2002 and 2008 with a median follow-up of approximately five years most of whom had a less aggressive form of PCa.
CNAs in tumor DNA samples from 125 patients in the discovery cohort who underwent prostatectomy were assayed with high-resolution Affymetrix 6.0 single-nucleotide polymorphism microarrays (Santa Clara, CA, USA) and then were analyzed using the Genomic Identification of Significant Targets in Cancer (GISTIC) algorithm.
The investigators found that changes in 20 gene regions were likely contribute to prostate cancer development and changes in seven of the 20 regions were linked with early death from prostate cancer. Patients whose cancer cells had a loss of the gene that encodes for phosphatase and tensin homolog protein (PTEN) and an amplification of the gene that encodes for myelocytomatosis viral oncogene homolog (MYC) were more than 50 times as likely to die from prostate cancer than other patients who had similarly staged tumors and prostate-specific antigen levels at the time of diagnosis. Analyses of 333 tumors from additional patients confirmed the link between PTEN and MYC and prostate cancer lethality.
The genetic changes involved in the development and progression of prostate cancer may help guide doctors as they weigh different treatment options for patients with the disease. Jianfeng Xu, MD, DrPh, the senior author said, “Prostate cancer patients who have DNA copy number alterations at PTEN and MYC may not be appropriate candidates for active surveillance and should be treated intensively.” The study was published on April 22, 2013, in the journal Cancer.
Related Links:
Wake Forest School of Medicine
Affymetrix
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans